TTFields for Mesothelioma 2026: 7 Reasons Insurers Still Call Optune Lua "Investigational"

Optune Lua has been FDA-approved for malignant pleural mesothelioma since May 2019. Eight years later, some private insurers still call it "investigational" and deny coverage when patients try to start treatment. The reason is not the device. The reason is the regulatory pathway it cleared — the Humanitarian Device Exemption (HDE), not the Premarket Approval (PMA) — and what that distinction signals to claims adjusters who are trained to anchor on the higher standard.^[1][4]

What Are Tumor Treating Fields (TTFields), and What Is Optune Lua?

Tumor Treating Fields are low-intensity, alternating electric fields delivered to a tumor through transducer arrays placed on the skin. For mesothelioma, the device is the Optune Lua system (originally branded NovoTTF-100L), built by NovoCure. Patients wear the arrays on the torso and run the device at 150 kHz for at least 18 hours per day, alongside first-line pemetrexed and platinum chemotherapy. The mechanism is mechanical and electrical: the alternating fields disrupt mitotic spindle formation, interfere with DNA repair, and trigger immunogenic cell death — without the systemic toxicity of additional chemotherapy.^[2]

For a deeper review of how the device works, what the trial data show across all approved indications, and how patients live with the equipment day to day, see our companion reference page on the WikiMesothelioma TTFields / Optune Lua overview.

Reason 1: Optune Lua for Mesothelioma Is the Only TTFields Indication Still Under HDE

The FDA approved the NovoTTF-100L on May 23, 2019, under the Humanitarian Device Exemption pathway, HDE number H180002.^[4][5] The approved indication is the treatment of adult patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma, used concurrently with pemetrexed and platinum-based chemotherapy.

Every other TTFields indication has since moved to — or originated under — the higher Premarket Approval pathway. The first two PMAs were in glioblastoma: recurrent GBM in 2011 (EF-11) and newly diagnosed GBM in 2015 (EF-14). Optune Lua received a PMA for metastatic non-small cell lung cancer in 2024 based on the phase 3 LUNAR trial. And in February 2026, the FDA approved Optune Pax for locally advanced pancreatic cancer via PMA, supported by the phase 3 PANOVA-3 randomized controlled trial.^[2]

Mesothelioma is now the lone HDE indication in NovoCure's U.S. portfolio. Claims adjusters who reviewed Optune Lua coverage in 2019 saw a single HDE indication. By 2026, they are looking at one HDE indication surrounded by four PMA approvals — and that contrast invites the question of why mesothelioma stayed put.

Reason 2: HDE Requires Only "Probable Benefit," Not Demonstrated Effectiveness

The Humanitarian Device Exemption pathway exists to encourage medical device development for rare conditions affecting fewer than 8,000 U.S. patients per year — mesothelioma, with roughly 3,000 new U.S. cases annually, qualifies. The trade-off is in the evidence required for approval. PMA requires the FDA to find that the device is safe and effective for its intended use. HDE only requires the FDA to find that the device's probable benefit outweighs its risk and that no comparable approved device exists.^[10]

The agency's own STELLAR approval document acknowledged the lower bar: "in the absence of a control group, statistical significance was not determined," and "the effectiveness of this device for this use has not been demonstrated."^[4][5] That language is regulatorily routine for HDE — it accompanies most HDE approvals — but it gives insurance medical directors who write coverage policy the exact phrase they need to classify the device as investigational. For a payer trained to read FDA letters as effectiveness signals, "the effectiveness has not been demonstrated" reads as the absence of the standard they require.

Reason 3: STELLAR Was a Phase 2, Single-Arm Trial

STELLAR (EF-23, NCT02397928) was a prospective, international, phase 2, single-arm trial that enrolled 80 patients with unresectable malignant pleural mesothelioma at 12 European sites between February 2015 and March 2017. Patients received continuous TTFields at 150 kHz for at least 18 hours per day plus up to six cycles of pemetrexed 500 mg/m² and platinum (cisplatin or carboplatin at investigator's choice). After completing chemotherapy, patients who remained progression-free continued TTFields as maintenance until disease progression or unacceptable toxicity.^[1][2]

The final results, published in The Lancet Oncology in October 2019 by Ceresoli and colleagues, were the strongest first-line mesothelioma data reported up to that point. Median overall survival was 18.2 months (95% CI: 12.1–25.8). One-year overall survival was 62.2% (95% CI: 50.3–72.0%). Two-year overall survival was 41.9% (95% CI: 28.0–55.2%). Median progression-free survival was 7.6 months (95% CI: 6.7–8.6). Among 72 evaluable patients, the objective response rate was 40% and the disease control rate was 97%. Median TTFields compliance during the first three months was 16.3 hours per day.^[1][2]

The results compared favorably to the Vogelzang 2003 historical control of 12.1 months on pemetrexed-cisplatin alone.^[3] But STELLAR did not include a randomized comparator arm. Independent reviewers — including a 2025 review by Ceresoli and Gianoncelli in Current Treatment Options in Oncology — have repeatedly emphasized that single-arm designs systematically overestimate efficacy versus randomized comparators, and that the 95% confidence interval for STELLAR's median OS overlaps broadly with first-line outcomes from MAPS (pemetrexed-cisplatin-bevacizumab, 18.8 months) and CheckMate 743 (nivolumab plus ipilimumab, 18.1 months).^[2]

"The STELLAR data are real, and they made TTFields the first new mesothelioma therapy in fifteen years. But a single-arm phase 2 of 80 patients is not the standard insurers use to retire the word 'investigational' — and it is not the standard NCCN uses for Category 1 endorsement. That is the gap." — Paul Danziger, Danziger & De Llano

Reason 4: NCCN and ASCO 2025 Guidelines Do Not Feature TTFields Prominently

Insurance medical directors regularly cite NCCN and ASCO guidelines as decisive evidence for medical-necessity decisions. In mesothelioma, both bodies have stayed conservative on TTFields.^[8][9] The NCCN Clinical Practice Guidelines for Malignant Pleural Mesothelioma, Version 2.2025, do not reference TTFields therapy. The ASCO 2025 Treatment of Pleural Mesothelioma guideline update — the first ASCO mesothelioma update since 2018 — focuses on surgical cytoreduction, immunotherapy (nivolumab plus ipilimumab; pembrolizumab plus chemotherapy), chemotherapy, pathology, and germline testing. TTFields is not among its strongly recommended options.^[9]

The reason both bodies keep TTFields out of their lead recommendations is the same: phase 3 randomized data typically underpin Category 1 endorsements, and STELLAR's single-arm design does not meet that bar. The German Onkopedia guidelines do include TTFields as a treatment option for pleural mesothelioma, reflecting the European CE certification — but U.S. coverage decisions are driven primarily by NCCN and ASCO. When a patient's insurer reviews a TTFields prior authorization in 2026, the insurer can cite the absence from both U.S. guidelines as direct evidence for an investigational classification.

Reason 5: No Phase 3 Randomized Mesothelioma Trial Is Registered

As of early 2026, no phase 3 randomized controlled trial of TTFields in mesothelioma has been registered on ClinicalTrials.gov, and NovoCure has not announced one as a near-term milestone. NovoCure's 2025 Annual Report (Form 10-K, filed February 2026) confirms that Optune Lua for mesothelioma remains approved under the HDE pathway and reports no PMA application for the mesothelioma indication.^[2]

The contrast with NovoCure's other indications is sharp. The company's regulatory pipeline currently centers on the METIS trial (PMA submitted December 2025 for brain metastases from non-small cell lung cancer; FDA decision expected in late 2026), the TRIDENT phase 3 trial for newly diagnosed glioblastoma (topline data expected in mid-2026), and the recently approved Optune Pax for pancreatic cancer (PANOVA-3, February 2026). Mesothelioma is not listed among NovoCure's anticipated 2025–2026 regulatory milestones.^[2]

Independent commentators including the editorial team at the International Lung Cancer News (ILCN) have called a randomized phase 3 mesothelioma trial "of paramount importance" to establish the device's true added benefit.^[6] Until such a trial is launched and reported, the evidence base will continue to consist of a single-arm phase 2 plus observational follow-on data — and that profile is what some insurers continue to read as investigational.

Reason 6: The February 2026 Optune Pax PMA Reinforces the Contrast

The pancreatic cancer approval is the most consequential 2026 development for Optune Lua's mesothelioma reimbursement environment, even though it is a different device for a different disease. PANOVA-3 was a phase 3, randomized, controlled trial. It produced PMA-pathway evidence, FDA effectiveness language, and the regulatory standard insurance medical directors are trained to recognize. After February 2026, every TTFields indication except mesothelioma sits on PMA-pathway data backed by a randomized trial.^[2]

For coverage purposes, this matters in two directions. On the one hand, it strengthens the broader credibility of the TTFields platform — payers can no longer treat the technology itself as fringe when three of four U.S. indications hold full PMA approvals. On the other hand, it sharpens the question for mesothelioma specifically: why has this indication not advanced? The most useful answer for a patient appealing a denial is straightforward — the rare-disease status that originally enabled the HDE pathway also means the patient population is too small to power a randomized phase 3 trial under standard commercial trial economics, and the device is FDA-approved and clinically available regardless. But that argument has to be made on the appeal letter, by the patient or the patient's advocate. It is not implicit in the denial language.

Reason 7: Real-World Compliance Gaps Reinforce Payer Skepticism

A subtler driver of investigational classifications is real-world compliance data. STELLAR achieved a median TTFields compliance of 16.3 hours per day (about 68% of the 24-hour day) in a controlled European trial cohort. A subsequent single-center U.S. real-world series reported a median compliance of 12.5 hours per day, with investigators citing hot or humid climate, patient frailty, and array adherence challenges as contributing factors.^[2]

The recommended dosing is at least 18 hours per day. Real-world undercompliance — well below the 75% threshold the device is engineered around — gives payer medical directors an additional argument for delaying coverage until more outcomes data are available in routine clinical care. The TIGER Meso registry (NCT05538806) was designed in part to address this: it is a NovoCure-sponsored, prospective, observational, real-world study currently enrolling approximately 198 patients across 23 centers, led by Dr. Giovanni Luca Ceresoli at Humanitas Gavazzeni Hospital in Bergamo. The study began in September 2022; its latest record update on ClinicalTrials.gov was August 18, 2025.^[7] TIGER Meso has no randomized comparator arm — it cannot replace a phase 3 trial — but it can provide the multi-center, multi-payer, real-world signal that some U.S. carriers now ask for before lifting an investigational designation.

What Should Patients Do When an Insurer Denies Coverage?

Most denials are not the end of the road. The standard playbook works for TTFields prior authorization just as it does for other complex oncology denials, and the appeal success rate is meaningful when the appeal is built on the FDA approval, the STELLAR publication, and the treating specialist's letter of medical necessity.

• Step 1 — Get the denial in writing. Request a written denial that cites the specific medical-necessity language used. Many "verbal denials" cannot survive an internal appeal because they fail to identify the policy provision being applied.
• Step 2 — File an internal appeal. Anchor the appeal on three documents: the FDA HDE approval (H180002), the Lancet Oncology STELLAR publication, and a letter of medical necessity from the treating mesothelioma specialist. State explicitly that Optune Lua is FDA-approved for unresectable malignant pleural mesothelioma — investigational classification under HDE is a payer interpretation, not an FDA finding.^[4][1]
• Step 3 — Use NovoCure's patient-access program. NovoCure operates a dedicated patient-support program that assists with prior authorization, appeals, and financial assistance for qualifying patients based on income and insurance status. Patients should contact this program early — ideally before the first prior authorization is filed — so the manufacturer can support the documentation package.
• Step 4 — If internal appeals fail, request external review. Most state insurance regulators provide an external review process for medical-necessity denials. The review is conducted by an independent physician or panel and is binding on the insurer. Mesothelioma denials reviewed externally tend to favor the patient when the FDA approval is properly cited.
• Step 5 — Pursue trust fund and civil claim recoveries in parallel. Patients with documented asbestos exposure can pursue asbestos trust fund claims and civil litigation regardless of insurance coverage status. Medical expenses for FDA-approved treatment — including TTFields — are recoverable as compensatory damages. For most mesothelioma patients, the legal-claims pathway closes the financial gap that private insurance leaves open.^[12]

Where Does Optune Lua Fit in the 2026 Mesothelioma Treatment Landscape?

For first-line treatment of unresectable malignant pleural mesothelioma, the 2026 standard of care has multiple options. The default for most patients — particularly those with non-epithelioid histology — is dual immunotherapy with nivolumab plus ipilimumab, established by the CheckMate 743 phase 3 trial. Pembrolizumab plus pemetrexed and platinum chemotherapy is FDA-approved as a first-line option following the IND.227 / KEYNOTE-483 results. Pemetrexed-platinum with or without bevacizumab remains an option for patients ineligible for immunotherapy. TTFields plus pemetrexed-platinum sits within this landscape as the only FDA-approved device-based therapy for mesothelioma — a fourth modality option for patients whose oncologists value the additional mechanism, who can sustain the daily wear time, and whose insurance coverage can be secured.

The decision is individualized. Treatment centers experienced with TTFields in mesothelioma — including the more than 110 U.S. hospitals certified to deliver the therapy — can structure protocols that include TTFields without delaying systemic therapy. Patients exploring this pathway should begin coverage discussions with their insurer at the same time they begin treatment-planning discussions with their oncologist, and should not assume that an initial denial is final.

Get Help Navigating Treatment and Coverage

Mesothelioma patients facing a TTFields coverage denial — or weighing whether to pursue Optune Lua at all — benefit from advocates who understand both the medical and the financial side of the disease. Our firm has worked with mesothelioma patients across the United States to coordinate access to FDA-approved treatments, navigate insurance appeals, and pursue compensation through asbestos trust fund claims and civil litigation when an exposure history is documented. There is no cost for an initial review, and any treatment-related medical expense recovery runs in parallel with — not instead of — your insurance coverage.

Additional patient resources are maintained at Danziger & De Llano's mesothelioma treatment overview, the MesotheliomaAttorney.com treatment advances page, and the WikiMesothelioma TTFields / Optune Lua reference page, which is updated as new regulatory and clinical-trial data are reported.

References

1. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology. 2019;20(12):1702-1709.
2. Ceresoli GL, Gianoncelli L. Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook. Current Treatment Options in Oncology. 2025.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003;21(14):2636-2644.
4. Humanitarian Device Exemption: NovoTTF-100L System (H180002). U.S. Food and Drug Administration AccessData.
5. FDA Approves the NovoTTF-100L System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma. NovoCure (May 2019).
6. TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the Constellation. International Lung Cancer News (ILCN), Editorial.
7. TTFields in General Routine Clinical Care in Patients with Pleural Mesothelioma (TIGER Meso) — NCT05538806. ClinicalTrials.gov, U.S. National Library of Medicine.
8. NCCN Clinical Practice Guidelines: Malignant Pleural Mesothelioma Version 2.2025. National Comprehensive Cancer Network.
9. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006-1038.
10. Humanitarian Device Exemption (HDE) Pathway Overview. U.S. Food and Drug Administration.
11. TTFields / Optune Lua for Mesothelioma. WikiMesothelioma.
12. Mesothelioma Treatment Options. Danziger & De Llano, LLP.
13. Mesothelioma Treatment Advances. MesotheliomaAttorney.com.